Good morning :)
Place Order
Add to Watchlist

SeQuent Scientific Ltd

SEQUENT

SeQuent Scientific Ltd

SEQUENT
Health CarePharmaceuticals
SmallcapWith a market cap of ₹5,088 cr, stock is ranked 783
High RiskStock is 3.80x as volatile as Nifty
192.651.92% (-3.78)
192.651.92% (-3.78)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹5,088 cr, stock is ranked 783
High RiskStock is 3.80x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

Avg

Average profitability - not good, not bad

Entry point

Avg

The stock is not in the overbought zone

Red flags

Avg

The stock has a moderate number of red flags

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹5,088 cr, stock is ranked 783
High RiskStock is 3.80x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
308.967.14—
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.906.610.52%

Forecast & Ratings

Detailed Forecast 
—
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

SeQuent Scientific Limited is a holding company that operates in pharmaceutical sector.

Investor Presentation

View older 

Nov 13, 2024

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 5.89%, vs industry avg of 9.03%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.48% to 0.37%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue621.08694.651,292.621,047.981,189.331,369.981,423.671,427.301,395.451,467.89
Raw Materialssubtract293.07366.89486.44570.52600.59733.68842.41814.87789.201,322.88
Power & Fuel Costsubtract26.5112.7714.6623.0624.7328.7533.8642.4535.46
Employee Costsubtract86.67106.22113.83145.95165.06187.22231.37258.39250.57
Selling & Administrative Expensessubtract55.1174.6894.7290.93108.27115.85132.65139.02138.35
Operating & Other expensessubtract89.6782.5964.2883.92110.2792.8663.12219.02126.88
Depreciation/Amortizationsubtract45.7240.0741.3441.9250.6250.6051.5455.6961.5465.29
Interest & Other Itemssubtract38.1528.3433.0732.8035.7124.3815.7735.5248.0955.69
Taxes & Other Itemssubtract4.65-3.0822.7210.2224.1741.1911.98-16.50-18.777.56
EPS-0.34-0.5315.981.912.823.841.65-4.87-1.440.66
DPS0.000.000.180.200.000.500.000.000.000.00
Payout ratio0.000.000.010.100.000.130.000.000.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2020

Annual report

PDF

Investor Presentation

Jan 28PDF
FY 2021

Annual report

PDF

Investor Presentation

Feb 3PDF
FY 2023

Annual report

PDF

Investor Presentation

May 23PDF
FY 2025

Annual Report Pending

Investor Presentation

Nov 13PDF
Sep 26PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
SeQuent Scientific Ltd-141.867.14—
Sun Pharmaceutical Industries Ltd45.106.440.75%
Cipla Ltd29.414.520.87%
Torrent Pharmaceuticals Ltd68.5016.550.84%

Price Comparison

Compare SEQUENT with any stock or ETF
Compare SEQUENT with any stock or ETF
SEQUENT
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Decreased Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has decreased by 1.59%

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding52.76%7.41%2.58%6.45%30.80%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep6.26%6.03%6.12%6.16%5.70%6.45%

Mutual Funds Holding Trend

Increased Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has increased by 1.73%

Top 5 Mutual Funds holding SeQuent Scientific Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
Quant Small Cap Fund - Growth - Direct Plan

Growth
8.5060%1.59%0.81%56/98 (+3)
Quant Healthcare Fund - Growth - Direct Plan

Growth
0.5379%6.23%1.91%7/27 (+5)
UTI Healthcare Fund - Growth - Direct Plan

Growth
0.3996%1.69%0.39%25/44 (+4)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 8, 2021

Final
Final | Div/Share: ₹0.50

Dividend/Share

₹0.50

Ex DateEx Date

Sep 8, 2021

Cash Dividend

Ex DateEx DateAug 21, 2019

Final
Final | Div/Share: ₹0.20

Dividend/Share

₹0.20

Ex DateEx Date

Aug 21, 2019

Cash Dividend

Ex DateEx DateNov 20, 2017

Interim
Interim | Div/Share: ₹0.20

Dividend/Share

₹0.20

Ex DateEx Date

Nov 20, 2017

Cash Dividend

Ex DateEx DateSep 16, 2011

Final
Final | Div/Share: ₹1.50

Dividend/Share

₹1.50

Ex DateEx Date

Sep 16, 2011

Cash Dividend

Ex DateEx DateSep 23, 2010

Final
Final | Div/Share: ₹2.00

Dividend/Share

₹2.00

Ex DateEx Date

Sep 23, 2010

News & Opinions
Corporate
Sequent Scientific allots 5.40 lakh equity shares under ESOP

Sequent Scientific has allotted 5,40,000 equity shares under ESOP on 23 November 2024. With this allotment, the paid up equity share capital has increased to Rs. Rs. 50,06,03,990/-consisting of 25,03,01,995 equity shares of Rs. 2/- each.Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Corporate
Sequent Scientific consolidates its holdings in N-VET AB, Sweden and Alivira Italia SRL, Italy

Sequent Scientific has completed the acquisition of 3.90% stake from Ms. Katarina Agren in N-VET AB through Alivira Animal Health, Ireland, Wholly Owned Subsidiary of the Company. The company also completed the acquisition of 3.75% stake from Renzo Rimondi and 1.25% from Ramon Vila Vina, collectively 5%, in Alivira Italia SRL, through Alivira Animal Health, Ireland, Wholly Owned Subsidiary of the Company. Consequent to the above acquisitions, N-VET AB and Alivira Italia SRL have become Wholly Owned Subsidiaries of the Company.Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Corporate
Sequent Scientific announces board meeting date

Sequent Scientific will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Sequent Scientific allots Equity Shares

Sequent Scientific has approved the issue and allotment of 120,000 Equity Shares of Rs. 2/- each fully paid to two Employees at an exercise price of Rs. 86/- per equity share on exercise of the options granted to them under SeQuent ESOP 2020. Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Sequent Scientific allots 60,000 equity shares under ESOP

Sequent Scientific has allotted 60,000 equity shares under ESOP on 16 October 2024. Consequent to the allotment of the aforesaid equity shares, the issued and the paid-up equity share capital of the Company will increase from Rs. 49,91,63,990/-consisting of 249581995 Equity Shares of Rs. 2/- each to Rs. Rs. 49,92,83,990/-consisting of 249641995 Equity Shares of Rs. 2/- each.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Sequent Scientific Ltd leads gainers in 'A' group

Force Motors Ltd, Dynamatic Technologies Ltd, Balrampur Chini Mills Ltd and Shree Renuka Sugars Ltd are among the other gainers in the BSE's 'A' group today, 27 September 2024.Sequent Scientific Ltd spiked 17.44% to Rs 223.6 at 11:47 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 13.31 lakh shares were traded on the counter so far as against the average daily volumes of 2.67 lakh shares in the past one month. Force Motors Ltd soared 7.97% to Rs 7516.15. The stock was the second biggest gainer in 'A' group. On the BSE, 21141 shares were traded on the counter so far as against the average daily volumes of 4192 shares in the past one month. Dynamatic Technologies Ltd surged 7.92% to Rs 7976. The stock was the third biggest gainer in 'A' group. On the BSE, 3071 shares were traded on the counter so far as against the average daily volumes of 2631 shares in the past one month. Balrampur Chini Mills Ltd rose 7.84% to Rs 660.55. The stock was the fourth biggest gainer in 'A' group. On the BSE, 3.69 lakh shares were traded on the counter so far as against the average daily volumes of 1.07 lakh shares in the past one month. Shree Renuka Sugars Ltd added 7.83% to Rs 51.89. The stock was the fifth biggest gainer in 'A' group. On the BSE, 61.14 lakh shares were traded on the counter so far as against the average daily volumes of 11.33 lakh shares in the past one month. Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Sequent Scientific to conduct AGM

Sequent Scientific announced that the Annual General Meeting (AGM) of the company will be held on 17 September 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Sequent Scientific receives WHO prequalification approval for Albendazole API

Sequent Scientific announced its receipt of prequalification (PQ) approval from the World Health Organization (WHO) for Albendazole, Active Pharmaceutical Ingredient (API). This is in partnership with Mepro Pharmaceuticals, who have successfully developed and commercialised the Albendazole Chewable formulation from its WHO PQ approved plant, using our API. Mepro's Chewable formulation is the first global approval of its kind by the WHO PQ. Albendazole is a vital medication used to treat a range of parasitic infections, including tapeworm, roundworm, and hookworm infestations, affecting millions globally, particularly in low and middle income countries. The WHO prequalification recognizes Sequent Scientific's commitment to stringent international standards in the production of Albendazole API, ensuring efficacy, safety, and quality. The WHO prequalification approval validates our manufacturing capabilities and reinforces our dedication to providing high-quality, affordable medicines to those in need worldwide. By leveraging our extensive distribution network and strategic partnerships, the company is poised to make a meaningful impact on health outcomes on a global scale,' said Rajaram Narayanan, MD & CEO of Sequent Scientific.Powered by Capital Market - Live

3 months agoCapital Market - Live
Spotlight
Sequent Scientific hits 52-week high after receiving prequalification approval for Albendazole

This is in partnership with Mepro Pharmaceuticals, who have successfully developed and commercialised the Albendazole Chewable formulation from its WHO PQ approved plant, using its API. Mepro's Chewable formulation is the first global approval of its kind by the WHO PQ. Albendazole is a vital medication used to treat a range of parasitic infections, including tapeworm, roundworm, and hookworm infestations, affecting millions globally, particularly in low and middle income countries. Rajaram Narayanan, MD & CEO of Sequent Scientific, said, 'The WHO prequalification approval validates our manufacturing capabilities and reinforces our dedication to providing high-quality, affordable medicines to those in need worldwide. By leveraging our extensive distribution network and strategic partnerships, the company is poised to make a meaningful impact on health outcomes on a global scale.' Sequent Scientific is a global pharmaceutical company specializing in Animal Health. With a strong international presence, the company operates in both API and formulation domains. Their focus lies in addressing unmet market needs for livestock, poultry, and companion animals. The company reported net profit of Rs 6.51 crore in Q1 FY25 as compared with net loss of Rs 34.85 crore in Q1 FY24. Net sales jumped 17.1% YoY to Rs 390.21 crore during the quarter. The counter hit 52-week high at Rs 175 in intraday today.Powered by Capital Market - Live

3 months agoCapital Market - Live
Earnings
Sequent Scientific reports consolidated net profit of Rs 6.51 crore in the June 2024 quarter

Net profit of Sequent Scientific reported to Rs 6.51 crore in the quarter ended June 2024 as against net loss of Rs 34.85 crore during the previous quarter ended June 2023. Sales rose 17.11% to Rs 390.21 crore in the quarter ended June 2024 as against Rs 333.21 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales390.21333.21 17 OPM %10.75-2.47 - PBDT28.25-17.93 LP PBT12.00-32.17 LP NP6.51-34.85 LP Powered by Capital Market - Live

3 months agoCapital Market - Live